WCG Blog

Insights from the WIRB-Copernicus Group

  • Essential Considerations for CTMS Integrations and Data Migrations

    Essential Considerations for CTMS Integrations and Data Migrations

    Read Post
  • NIH Launches NExTRAC to Advise on Emerging Biotechnologies

    NIH Launches NExTRAC to Advise on Emerging Biotechnologies

    Read Post
  • 2020 Prospectus
  • Be the Site of Choice

    Be the Site of Choice

    In early October, over hundreds of representatives of clinical research sites and members from biopharmaceutical companies came together for WCG’s Global Research Network™ Be the Site of Choice Event.

    Read Post
  • An Overview of the Recent SACHRP Recommendations Around Payments in Clinical Research

    An Overview of the Recent SACHRP Recommendations Around Payments in Clinical Research

    Read Post
  • What if Patients and Patient Advocates Spoke About Clinical Trial Participation and the Key Issues that Affected Trial Participation?

    What if Patients and Patient Advocates Spoke About Clinical Trial Participation and the Key Issues that Affected Trial Participation?

    A forum to gather Patient Advocacy Groups, their constituents, and key stakeholders in drug development to advance and insist upon meaningful change in clinical research.

    Read Post
  • In the Gut, In the Environment, On the iPad: Emerging Developments in Autism Research

    In the Gut, In the Environment, On the iPad: Emerging Developments in Autism Research

    We are, at last, beginning to better understand the broad range of phenotypic differences in what we classify as autism spectrum disorders.

    Read Post
  • ×

    First Name
    Last Name
    Company
    Thank you!
    Error - something went wrong!
  • Lessons Learned from 600+ Expert Committee Members

    Lessons Learned from 600+ Expert Committee Members

    We asked our network of over 600 experts to share with us what they think makes an expert committee successful.

    Read Post
  • Your 5 Questions About Enrollment Assistants Answered

    Your 5 Questions About Enrollment Assistants Answered

    Read Post
  • What You Don’t Know About Patient Recruitment Can Impede the Success of Your Trial

    What You Don’t Know About Patient Recruitment Can Impede the Success of Your Trial

    Read Post
  • Get under the hood while the trial is running: Identify and rectify data problems before it's too late

    Get under the hood while the trial is running: Identify and rectify data problems before it's too late

    How can sponsors maximize assay and endpoint sensitivity? And are you meeting scientific and regulatory expectations for quality data in clinical trials?

    Read Post
  • De-risking Clinical Trials Through Analytic Supported, On-Demand Medical Expertise From The World’s Leading Clinical Trial Experts

    De-risking Clinical Trials Through Analytic Supported, On-Demand Medical Expertise From The World’s Leading Clinical Trial Experts

    Read Post
  • 4 Tips to Bolster Your Regulatory Strategy

    4 Tips to Bolster Your Regulatory Strategy

    Read Post
  • To Mitigate Placebo Response, Test, Train and Control Expectations

    To Mitigate Placebo Response, Test, Train and Control Expectations

    The placebo effect: it’s the curse of clinical trials across indications. Luckily, training patients to accurately report their symptoms has been proven to reduce placebo response.

    Read Post
  • Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research

    Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research

    On April 25th, NIH Director Francis Collins announced the release of the amended NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The most important take-home...

    Read Post
  • 4 Recurring Risks to Consider in Early Phase CNS Research

    4 Recurring Risks to Consider in Early Phase CNS Research

    Early phase CNS research is plagued by a higher than average failure rate and complicated by a lack of discreet endpoints. So how can sponsors ameliorate their chances of success from the start?

    Read Post
  • CNS Science Has Outpaced Tool Development; It’s Time to Catch Up

    CNS Science Has Outpaced Tool Development; It’s Time to Catch Up

    For the first time in decades, we’re developing CNS drugs with new mechanisms of action. Unfortunately, our measurement tools are stuck in the past.

    Read Post
  • Site Score Card: Expert Tips for Moving Up the Ranks

    Site Score Card: Expert Tips for Moving Up the Ranks

    How can a site move up the selection list and participate in these trials? It’s as simple as one word: metrics.

    Read Post
  • Unique Challenges for Medical Device Clinical Trials

    Unique Challenges for Medical Device Clinical Trials

    Adjudication of events of interest can support overall study integrity and ensure reliable, consistent definitions are provided to regulators and the scientific community.

    Read Post
  • Single-Patient Expanded Access: WIRB experience in 2018

    Single-Patient Expanded Access: WIRB experience in 2018

    In 2018 WIRB approved 100% of the single-patient EA requests that were submitted for review.

    Read Post
  • Is the Government Shutdown Already Impacting Drug Development?

    Is the Government Shutdown Already Impacting Drug Development?

    For biopharma sponsors, investigators, patients and families, these limitations are already translating into real impacts on development programs.

    Read Post
  • loading
    Loading More...